JP2013520200A - ペプチド固定化表面をγ線劣化から保護するための修飾基板 - Google Patents
ペプチド固定化表面をγ線劣化から保護するための修飾基板 Download PDFInfo
- Publication number
- JP2013520200A JP2013520200A JP2012555045A JP2012555045A JP2013520200A JP 2013520200 A JP2013520200 A JP 2013520200A JP 2012555045 A JP2012555045 A JP 2012555045A JP 2012555045 A JP2012555045 A JP 2012555045A JP 2013520200 A JP2013520200 A JP 2013520200A
- Authority
- JP
- Japan
- Prior art keywords
- cell culture
- peptide
- culture substrate
- coating
- methionine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000758 substrate Substances 0.000 title claims abstract description 46
- 230000005251 gamma ray Effects 0.000 title claims 4
- 230000015556 catabolic process Effects 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 238000000576 coating method Methods 0.000 claims abstract description 119
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 106
- 239000011248 coating agent Substances 0.000 claims abstract description 88
- 238000004113 cell culture Methods 0.000 claims abstract description 64
- 229930182817 methionine Natural products 0.000 claims abstract description 21
- 239000003381 stabilizer Substances 0.000 claims abstract description 19
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 18
- 230000000903 blocking effect Effects 0.000 claims abstract description 9
- 239000000816 peptidomimetic Substances 0.000 claims abstract description 9
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 6
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 6
- 235000000346 sugar Nutrition 0.000 claims abstract description 5
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 4
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 235000001014 amino acid Nutrition 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 239000011241 protective layer Substances 0.000 claims description 8
- 239000000853 adhesive Substances 0.000 claims description 7
- 230000001070 adhesive effect Effects 0.000 claims description 7
- 235000018102 proteins Nutrition 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 230000006866 deterioration Effects 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000011593 sulfur Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- JPFGFRMPGVDDGE-GWRCVIBKSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-2,3,4-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O)[C@@](O)(CO)OC1 JPFGFRMPGVDDGE-GWRCVIBKSA-N 0.000 claims 1
- GZCGUPFRVQAUEE-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxyhexanal Chemical compound OCC(O)C(O)C(O)C(O)C=O GZCGUPFRVQAUEE-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 230000003064 anti-oxidating effect Effects 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 235000021310 complex sugar Nutrition 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 229940081974 saccharin Drugs 0.000 claims 1
- 235000019204 saccharin Nutrition 0.000 claims 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 36
- 239000003963 antioxidant agent Substances 0.000 abstract description 32
- 230000003078 antioxidant effect Effects 0.000 abstract description 22
- 230000000975 bioactive effect Effects 0.000 abstract description 8
- 108010031318 Vitronectin Proteins 0.000 abstract description 4
- 102100035140 Vitronectin Human genes 0.000 abstract description 4
- 210000001671 embryonic stem cell Anatomy 0.000 abstract description 3
- 241000894007 species Species 0.000 abstract description 3
- 230000006641 stabilisation Effects 0.000 abstract description 2
- 238000011105 stabilization Methods 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 229920001308 poly(aminoacid) Polymers 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 76
- 210000004027 cell Anatomy 0.000 description 68
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 38
- 230000001954 sterilising effect Effects 0.000 description 30
- 235000006708 antioxidants Nutrition 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 238000004659 sterilization and disinfection Methods 0.000 description 26
- 239000000203 mixture Substances 0.000 description 20
- 239000000356 contaminant Substances 0.000 description 17
- 150000002148 esters Chemical class 0.000 description 17
- 229960004452 methionine Drugs 0.000 description 17
- 244000052769 pathogen Species 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 230000005855 radiation Effects 0.000 description 16
- 150000003839 salts Chemical class 0.000 description 16
- 230000008901 benefit Effects 0.000 description 14
- 239000008367 deionised water Substances 0.000 description 14
- 229910021641 deionized water Inorganic materials 0.000 description 14
- 108010082117 matrigel Proteins 0.000 description 14
- 230000008569 process Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 10
- -1 NHS ester Chemical class 0.000 description 10
- 238000004806 packaging method and process Methods 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 239000012620 biological material Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 8
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 8
- 229960005070 ascorbic acid Drugs 0.000 description 8
- 235000010323 ascorbic acid Nutrition 0.000 description 8
- 239000011668 ascorbic acid Substances 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229940116269 uric acid Drugs 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 239000000017 hydrogel Substances 0.000 description 6
- 150000002741 methionine derivatives Chemical class 0.000 description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 6
- 239000011253 protective coating Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 5
- 108091000054 Prion Proteins 0.000 description 5
- 239000008199 coating composition Substances 0.000 description 5
- 239000002274 desiccant Substances 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- RLNWRDKVJSXXPP-UHFFFAOYSA-N tert-butyl 2-[(2-bromoanilino)methyl]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1CNC1=CC=CC=C1Br RLNWRDKVJSXXPP-UHFFFAOYSA-N 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 241000204031 Mycoplasma Species 0.000 description 4
- 102000029797 Prion Human genes 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 150000003862 amino acid derivatives Chemical class 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 241000219289 Silene Species 0.000 description 3
- 241000202898 Ureaplasma Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000003235 crystal violet staining Methods 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 238000010894 electron beam technology Methods 0.000 description 3
- 239000012632 extractable Substances 0.000 description 3
- UIHPNZDZCOEZEN-YFKPBYRVSA-N methyl (2s)-2-amino-4-methylsulfanylbutanoate Chemical compound COC(=O)[C@@H](N)CCSC UIHPNZDZCOEZEN-YFKPBYRVSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000010388 propyl gallate Nutrition 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 102100034452 Alternative prion protein Human genes 0.000 description 2
- 101800000068 Antioxidant peptide Proteins 0.000 description 2
- 244000132059 Carica parviflora Species 0.000 description 2
- 235000014653 Carica parviflora Nutrition 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 230000008275 binding mechanism Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 125000004386 diacrylate group Chemical group 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 210000002242 embryoid body Anatomy 0.000 description 2
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 208000010544 human prion disease Diseases 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- MEVUPUNLVKELNV-JEDNCBNOSA-N methyl (2s)-2-amino-4-methylsulfanylbutanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CCSC MEVUPUNLVKELNV-JEDNCBNOSA-N 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229950004354 phosphorylcholine Drugs 0.000 description 2
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- RIWRBSMFKVOJMN-UHFFFAOYSA-N 2-methyl-1-phenylpropan-2-ol Chemical compound CC(C)(O)CC1=CC=CC=C1 RIWRBSMFKVOJMN-UHFFFAOYSA-N 0.000 description 1
- NFFCPZZYYGLLFL-UHFFFAOYSA-N 3-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxylic acid Chemical compound C1C(O)C(C)(C(O)=O)OC2=C(C)C(C)=CC(C)=C21 NFFCPZZYYGLLFL-UHFFFAOYSA-N 0.000 description 1
- CYUZOYPRAQASLN-UHFFFAOYSA-N 3-prop-2-enoyloxypropanoic acid Chemical compound OC(=O)CCOC(=O)C=C CYUZOYPRAQASLN-UHFFFAOYSA-N 0.000 description 1
- OGELTFZRACUWNA-UHFFFAOYSA-N 5,6,7,8-tetramethyl-3,4-dihydro-2h-chromene-2-carboxylic acid Chemical compound O1C(C(O)=O)CCC2=C(C)C(C)=C(C)C(C)=C21 OGELTFZRACUWNA-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 101000693922 Bos taurus Albumin Proteins 0.000 description 1
- 108010002217 Calcifying Nanoparticles Proteins 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001533384 Circovirus Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- 241000549556 Nanos Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000003848 UV Light-Curing Methods 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 1
- 229960004352 diosmin Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/20—Small organic molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
Abstract
Description
1) 共有結合により、抗酸化剤の相分離または結晶化が防がれ、これにより、均一な分布および保護の効率が保証される;
2) 結合プロセスに追加の工程が必要ない;
3) 抗酸化分子が保護対象により近い。これにより、保護効率がさらに増加する;
4) 抗酸化分子は表面に共有結合し、したがって、抽出可能物質が導入されず、細胞培養前に追加の洗浄が必要ない;
5) 一般に、様々なタイプのペプチド結合表面を、γ線滅菌中、並びにプロセスストレス中および長期の貯蔵中に保護することが可能である。
1. 抗酸化剤および安定剤は、普遍保護層として働くことができる、すなわち、ペプチドおよび組換えECM蛋白質を含む全ての生物学的リガンドを、γ線照射を含む最終滅菌から保護できる;
2. 一般に、様々なタイプのペプチド結合表面を、γ線滅菌中および長期の貯蔵中に保護することが可能である;
3. 抗酸化剤および安定剤を組み合わせて、機能および費用対効果を改善することができる;
4. 薄い被覆は、除去する必要がないかもしれない、または細胞に毒作用を与えずに、水中に溶解させることによって、容易に除去できる;
5. 総製造原価に最小の費用しか加わらない。
1. 犠牲層として使用され、細胞培養前に除去されるペプチドは、結合可能なペプチドと同じであるので、改良された(re-vamped)GMP検証は必要ない;
2. 接着性ペプチド被覆は、費用の影響を減少させるために、非常に薄い被覆中に低濃度で施される;
3. 接着性ペプチドは容易に除去される;
4. 接着性ペプチドは、γ線照射に対する万能保護剤として使用できる。
材料および方法
アクリレート被覆:メタクリル酸2−ヒドロキシエチル、アクリル酸2−カルボキシエチル、ジメタクリル酸テトラ(エチレングリコール)、Darocur1173、Irgacure819を80:20:2:2:0.1の比率で混合し、5%の総モノマー濃度でエタノール中に溶解させた。得られた配合物を、酸素プラズマ処理済みZeonor膜上にスピンコートした。エタノールを蒸発させた後、窒素パージしたボックス内でキセノンパルスUV硬化システムを使用して、(メタ)アクリレート被覆を硬化させた。次いで、被覆された膜をT−75Zeonorフラスコ中にインモールドラベル(in-mold-labeled)し、結合のために直接使用した。
アミノ酸吸収:培養の4日後の細胞計数を使用して、γ線滅菌後のペプチドアクリレート表面の生物活性への影響を示した。どのような処理も行わずには、H7は、図1に「処理なし」により示されるように、γ線照射したVN−ペプチド表面に接着できない。メチオニンエステル処理済みVN−ペプチドアクリレート表面上では、γ線照射後に生物活性が維持された。このことが、図1に示されるように、γ線照射を行わなかった表面(ETOH対照)および「Matrigel」(我々のベンチマーク表面)の細胞数に対して、メチオニン処理した表面上の匹敵する細胞数によって、実証された。メチオニン処理により、幹細胞形態も陽性対照に匹敵した。
材料および方法:
i)アクリレート被覆の調製:全てのアクリレート被覆は、方法1に先に記載したように調製した。調製後、ペプチド結合実験に使用する準備ができるまで、全てのフラスコに蓋をして室温で貯蔵した。
糖蛋白質、糖、抗酸化剤、遊離ラジカル捕捉剤、アミノ酸および多価アルコールなどの安定剤の異なる組合せを、適切な溶媒中の様々な質量パーセント組成を使用して、被覆へと計画的に配合した。フラスコ上の被覆の厚さに関する図4(A,B)に示されるように、被覆配合物に応じて、各フラスコ上にそれぞれの被覆の厚い層を形成した。異なる被覆配合物を収容する8つのフラスコの各々は、γ線照射後に被覆を除去するための洗浄中に様々な難易度を有した。
材料および方法
i)アクリレート被覆の調製:説明については先の実施例1参照。
図7において、1mMのVN被覆(エタノール中)(γ線照射後に被覆が洗い流された)および1質量%のメチオニン被覆を有する新規の抗酸化ペプチド(γ線照射後に被覆が洗い流された)が被覆された、γ線照射後の1mMのVNペプチド結合ペプチド−アクリレートフラスコ上で培養したhESC H7細胞についての結果が示されている。この研究のみについて、細胞形態を毎日評価し、細胞計数および生存率について、細胞を4日目に収穫した。未洗浄の被覆(データは示さず)について、細胞は付着しなかったが、「洗い流された」被覆については、細胞数(図7参照)および形態(図8参照)は、エタノールおよび「Matrigel」対照フラスコ上の細胞のものに匹敵した。
Claims (5)
- γ線照射による未修飾細胞培養基板の劣化から保護し、安定化させる修飾細胞培養基板であって、前記修飾細胞培養基板が、該細胞培養基板の表面に結合した保護層を含み、該保護層が、ペプチド模倣表面を前記γ線照射から保護し安定化させるのに効果的な濃度で未反応のn−ヒドロキシスクシンイミド基の抑制(ブロッキング)と考えられる後ペプチド結合のための硫黄含有アミノ酸または該硫黄含有アミノ酸のペプチド短鎖を含むことを特徴とする未修飾細胞培養基板。
- γ線照射による未修飾細胞培養基板の劣化から保護し、安定化させる修飾細胞培養基板であって、前記修飾細胞培養基板が、該細胞培養基板の表面に被覆された保護層を含み、該被覆された保護層が、単糖と複合糖、炭水化物、糖蛋白質、親水性ポリマー、蛋白質、短いメチオニンを含有するペプチド、アミノ酸に類似の小分子およびビタミンA,C,EおよびPを含む、抗酸化剤と安定剤との組合せを含むことを特徴とする未修飾細胞培養基板。
- γ線照射による未修飾細胞培養基板の劣化から保護し、安定化させる修飾細胞培養基板であって、前記修飾細胞培養基板が、該細胞培養基板の表面に被覆された保護層を含み、該被覆された保護層が、少なくとも1から5のメチオニンアミノ酸残基を含有する接着性ペプチドを含むことを特徴とする未修飾細胞培養基板。
- 前記硫黄含有アミノ酸が、ペプチド結合後に、任意の残留または未反応n−ヒドロキシスクシンイミド反応性基に結合されたメチオニンエステル塩であることを特徴とする請求項1記載の未修飾細胞培養基板。
- 前記被覆された保護層が、グルコース、スクロース、フルクトース、トレハロース、D−マンノース、D,L−ガラクトース、D−ソルビトール、サッカリンおよびD−ロイクロースを含む糖を含むことを特徴とする請求項2記載の未修飾細胞培養基板。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30712610P | 2010-02-23 | 2010-02-23 | |
US61/307,126 | 2010-02-23 | ||
PCT/US2011/025138 WO2011106222A2 (en) | 2010-02-23 | 2011-02-17 | Modified substrates for protection of peptide-immobilized surfaces from gamma radiation degradation |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013520200A true JP2013520200A (ja) | 2013-06-06 |
JP2013520200A5 JP2013520200A5 (ja) | 2016-08-25 |
JP6025256B2 JP6025256B2 (ja) | 2016-11-16 |
Family
ID=44312374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012555045A Expired - Fee Related JP6025256B2 (ja) | 2010-02-23 | 2011-02-17 | ペプチド固定化表面をγ線劣化から保護するための修飾基板 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10144914B2 (ja) |
EP (1) | EP2539435A2 (ja) |
JP (1) | JP6025256B2 (ja) |
WO (1) | WO2011106222A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012080836A (ja) * | 2010-10-13 | 2012-04-26 | Toyo Seikan Kaisha Ltd | 接着細胞用培養容器、及び接着細胞用培養容器の製造方法 |
KR20150108638A (ko) * | 2014-03-18 | 2015-09-30 | 삼성전자주식회사 | 결빙 방지 부재 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6080777B2 (ja) | 2011-03-17 | 2017-02-22 | コーニング インコーポレイテッド | 細胞培養のための合成被覆 |
FR2998493B1 (fr) * | 2012-11-27 | 2015-02-13 | Commissariat Energie Atomique | Procede de formation d'un film liquide sur un support |
EP3830237A1 (en) * | 2018-08-16 | 2021-06-09 | TERUMO Kabushiki Kaisha | Cell culture substrate |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4999297A (en) * | 1986-05-30 | 1991-03-12 | Director-General Of Agency Of Industrial Science And Technology | Culture of cells |
JPH08205893A (ja) * | 1994-12-08 | 1996-08-13 | Sumitomo Metal Ind Ltd | Hcvプロテアーゼ活性測定法 |
US20090191632A1 (en) * | 2008-01-30 | 2009-07-30 | Fadeev Andrei G | Swellable (meth)acrylate surfaces for culturing cells in chemically defined media |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2832689A (en) * | 1952-01-24 | 1958-04-29 | Research Corp | Preservation of organic materials by irradiation |
US5256767A (en) * | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
US5283034A (en) * | 1989-06-29 | 1994-02-01 | Applied Immune Sciences, Inc. | Stabilization of sterilized surfaces for research and medical use |
US5981163A (en) * | 1990-05-15 | 1999-11-09 | New York Blood Center, Inc. | Process for the sterilization of biological compositions using irradiation and quenchers of type I and type II photodynamic reactions |
WO1993016185A2 (en) * | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
US5362442A (en) * | 1993-07-22 | 1994-11-08 | 2920913 Canada Inc. | Method for sterilizing products with gamma radiation |
US6479533B1 (en) * | 1997-02-20 | 2002-11-12 | Applied Genetics Incorporated Dermatics | Methods and compositions for the protection of mitochondria |
JP3101875B2 (ja) | 1998-12-04 | 2000-10-23 | 末綱 陽子 | 新規なトリペプチドおよび活性化酸素阻害剤 |
US6682695B2 (en) | 2001-03-23 | 2004-01-27 | Clearant, Inc. | Methods for sterilizing biological materials by multiple rates |
US6787179B2 (en) * | 2001-06-29 | 2004-09-07 | Ethicon, Inc. | Sterilization of bioactive coatings |
US20030031584A1 (en) * | 2001-08-10 | 2003-02-13 | Wilson Burgess | Methods for sterilizing biological materials using dipeptide stabilizers |
US7252799B2 (en) * | 2001-08-31 | 2007-08-07 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
US20030064000A1 (en) * | 2001-09-24 | 2003-04-03 | Wilson Burgess | Methods of sterilizing biological mixtures using stabilizer mixtures |
AU2004312090B2 (en) | 2003-12-31 | 2008-08-14 | The Board Of Regents, The University Of Texas System | Pharmaceutical composition for thrombin peptide derivatives |
US7655393B2 (en) * | 2004-05-11 | 2010-02-02 | Shukokai Incorporated | Adoptive immune cells for tumor vaccines |
US20060002985A1 (en) * | 2004-07-02 | 2006-01-05 | Zicker Steven C | Compositions and methods for decreasing age-related deterioration in mental activities in companion animals |
WO2006130869A1 (en) * | 2005-06-02 | 2006-12-07 | Alza Corporation | Method for terminal sterilization of transdermal delivery devices |
EP1767225A1 (en) * | 2005-09-21 | 2007-03-28 | Insense Limited | Method for stabilisation of a protein solution by addition of hydroxyl radical quenchers and its sterilisation by ionising radiation |
EP1852443A1 (en) | 2006-05-05 | 2007-11-07 | Leukocare AG | Biocompatible three dimensional matrix for the immobilization of biological substances |
US9670462B2 (en) * | 2006-05-24 | 2017-06-06 | Agency For Science, Technology And Research | Bioactive surface for hepatocyte-based applications |
EP2183289A2 (en) * | 2007-08-31 | 2010-05-12 | Corning Incorporated | Reactive surface on a polymeric substrate |
WO2009111022A1 (en) * | 2008-03-07 | 2009-09-11 | Corning Incorporated | Hydrophobically modified cellulose ether derivatives for cell culture and release |
-
2011
- 2011-02-17 WO PCT/US2011/025138 patent/WO2011106222A2/en active Application Filing
- 2011-02-17 JP JP2012555045A patent/JP6025256B2/ja not_active Expired - Fee Related
- 2011-02-17 EP EP11707518A patent/EP2539435A2/en not_active Withdrawn
- 2011-02-22 US US13/032,166 patent/US10144914B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4999297A (en) * | 1986-05-30 | 1991-03-12 | Director-General Of Agency Of Industrial Science And Technology | Culture of cells |
JPH08205893A (ja) * | 1994-12-08 | 1996-08-13 | Sumitomo Metal Ind Ltd | Hcvプロテアーゼ活性測定法 |
US20090191632A1 (en) * | 2008-01-30 | 2009-07-30 | Fadeev Andrei G | Swellable (meth)acrylate surfaces for culturing cells in chemically defined media |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, vol. 84, no. 4, JPN6015016348, 2008, pages 988 - 993, ISSN: 0003059690 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012080836A (ja) * | 2010-10-13 | 2012-04-26 | Toyo Seikan Kaisha Ltd | 接着細胞用培養容器、及び接着細胞用培養容器の製造方法 |
KR20150108638A (ko) * | 2014-03-18 | 2015-09-30 | 삼성전자주식회사 | 결빙 방지 부재 |
KR102274376B1 (ko) * | 2014-03-18 | 2021-07-08 | 삼성전자주식회사 | 결빙 방지 부재 |
Also Published As
Publication number | Publication date |
---|---|
WO2011106222A3 (en) | 2011-11-24 |
US10144914B2 (en) | 2018-12-04 |
JP6025256B2 (ja) | 2016-11-16 |
EP2539435A2 (en) | 2013-01-02 |
WO2011106222A2 (en) | 2011-09-01 |
US20110207219A1 (en) | 2011-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Galante et al. | Sterilization of hydrogels for biomedical applications: A review | |
US9011894B2 (en) | Sterile hyaluronic acid polymer compositions and related methods | |
JP6025256B2 (ja) | ペプチド固定化表面をγ線劣化から保護するための修飾基板 | |
US20060280769A1 (en) | Terminal sterilization of injectable collagen products | |
JP6412477B2 (ja) | 生物機能性組成物の滅菌の手段および方法 | |
EP0710124B1 (en) | Method for sterilizing products | |
US7848487B2 (en) | Methods for sterilizing biological materials containing non-aqueous solvents | |
JP7619961B2 (ja) | 糖リン脂質ポリマーネットワーク及びその使用 | |
JP2003527210A (ja) | 生体材料を滅菌するための方法 | |
US11845813B2 (en) | Crosslinked polymeric network and use thereof | |
RU2591829C2 (ru) | Электронно-лучевая стерилизация медицинского устройства с биоактивным покрытием | |
Liu et al. | Phosphorylated chitosan hydrogels inducing osteogenic differentiation of osteoblasts via JNK and p38 signaling pathways | |
Baume et al. | Sterilization of tissue scaffolds | |
EP1758618A2 (en) | Methods of sterilizing biological mixtures using alpha-keto acids | |
WO2012175917A1 (en) | Method of decontamination and sterilisation | |
Saeed et al. | In vitro evaluation of decontamination effects on mechanical properties of fibrin membrane | |
JP2000135275A (ja) | 人工皮膚基材又は細胞培養用基材の滅菌方法 | |
EP4389821A1 (en) | Hydrogel and sterilized dry hydrogel-forming article | |
Pettit et al. | Crystal M. Cunanan, 1 Richard S. Graham, 1 Nicholas J. Manesis, 2 | |
CS274204B1 (en) | Cultivation support plate or implant | |
HK1057181A (en) | Methods for sterilizing biological materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150428 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150728 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150828 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150908 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160202 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160502 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20160704 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160913 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161007 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6025256 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |